Study on Binding of Apoprotein of Lidamycin to Cancer Cells
WANG Jian-kang1，2，MENG Ru-song1，LI Zhong-dong1
Author information+
1. General Hospital of Air Force，Beijing 100036，China；2.Institute of Medicinal Biotechnology，Academy of Medical Science ＆ Peking Union Medical College，Beijing 100050，China
OBJECTIVE This experiment was set to study binding of the apoprotein to cancer cells and examine the correlation between the binding action and cancer biological index such as ER、P53、Bcl-2. METHODS LDP was linked to FITC, a fluorescent reagent. The FITC-LDP conjugate was incubated with cancer tissue specimens at a certain condition. Fluorescent microscope was used to observe fluorescent intensity of specimens. The fluorescent intensity were graded into 3 levels which included positive, doubtful and negative. The expression of cancer biological index was observed by the method of immunohistochemistry, the staining of which were also graded into 3 levels which contained positive, doubtful and negative. Kappa test or Spearman test were used to analyze the above correlation. RESULTS Only a fraction of breast cancer tissue specimen displayed positive fluorescent staining caused by FITC-LDP conjugate. 2 out of 3 iced specimens showed positive fluorescent staining. 11, 4 or 5 out of 20 wax specimens showed positive, doubtful and negative fluorescent staining, respectively. The fluorescent staining and ER, P53 or Bcl-2 immunohistochemistry staining had respective concordance with Kappa test ( P<0.05 ). The fluorescent staining and ER, P53 or Bcl-2 immunohistochemistry staining showed negative rank correlation, positive rank correlation and no rank correlation respectively with Spearman test(P<0.05). CONCLUSION LDP may have binding action on breast cancer cells, which might exist negative or positive correlation with ER or mutant P53 protein of breast cancer, respectively.
WNG Jin-kng;MENG Ru-song;LI Zhong-dong.
Study on Binding of Apoprotein of Lidamycin to Cancer Cells [J]. Chinese Pharmaceutical Journal, 2008, 43(16): 1228-1233
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] HU J L，XUE Y C，XIE M Y，et al. A new macromolecular antitumor antibiotics，C-1027 discovery，taxonomy of producing organism fermentation and biological activity[J] . Antibiotics，1988，41(11)：1575-1579.
[2] OTANI T，MINAMI Y，MARUNAKA T，et al. A new macromolecular antitumor antiobiotic，C-1027 isolation and physico-chemical properties[J] . Antibiotics，1988，41 (11) ：1580-1585.
[3] ZHEN Y S，MING X Y，YU B，et al. A new macromolicular antitumor antibiotic，C-1027. Antitumor activity[J] . Antibiotics，1989，42 (8)：1294-1298.
[4] SUGIURA Y，MATSUMOTO T. Some characteristics of DNA strand scission by macro-molecular antitumor antibiotic C-1027 containing a novel enediyne chromophore[J] . Biochemistry，1993，32(21)：5548-5553.
[5] XU Y J，ZHEN Y S ，GOLDBERG I H. C1027 chromophore，a potent new enediyne antitumor antibiotic，induces sequence-specific double-strand DNA cleavage[J] . Biochemistry，1994，33(19)：5947-5954.
[6] SUN Y W，LI D D，ZHEN Y S. Advances in antitumor research of C1027，an enediyne macromolecular antitumor antibiotics[J] . Pharm Biotech(药物生物技术)，1998，5（4）：252-256.
[7] SHAO R G， ZHEN Y S. Study progresses of high effective enediyne antibiotic[J] . World Notes Antibiot(国外医药·抗生素分册)，1995，16(3) ：194-199.
[8] ZHEN Y ，XUE Y C，SHAO R G. Antitumor activity of the new enediyne antibiotic C1027[J] . Chin J Antibio(中国抗生素杂志)，1994，19(2)：164-168.
[9] OTANI T，YASUHARA T，MINAMI Y，et al. Purification and primary structure of C-1027-AG，a selective anagonist of antitumor antibiotic C-1027 from Strptomyces globisporus[J] . Agric Biol Chem，1991，55(2)：407-419.
[10] RUAN Y B. Immuno-Flurescent Foundation. Experimental New Principle and Its Clinical New Application（免疫荧光基础. 实验新原理和它的临床新应用）[M] . Beijing：People’s Medical Publishing House，2000：8-76.
[11] PEI J，YU C J，WANG B Z，et al. Study of expression and clinicopathologic correlation of ER、PR、HER-2 in postmenopausal women with breast invasion ductal carcinoma[J] . Acta Univ Med Anhui（安徽医科大学学报），2005，40（1）：41-43.
[12] SPEIRS V，KERIN M J. Prognostic significance of estrogen receptor beta in breast cancer[J] . Br J Surg，2000，87(4)：405-409.
[13] VASCONCELOS A，MEDEIROS R，VEIGA L，et al. Analysis of estrogen receptor，polymorphism in codon 325 by PCR-SSCP in breast cancer：association with lymph node metastasis[J] . Breast J，2002，8(4)：226-229.
[14] LIU Y H，QIU Y. Application of immunocyte chemical assay in the diagnosis and treatment of breast cancer[J] .Foreign Med Sci (Cancer Sec)(国外医学·肿瘤学分册)，2000，27(3)：165-167.
[15] MIRZA A，MCGUIRK M，HOCKENBERRY T N，et al. Humansur-vivin is negatively regulated by wildtype p53 and participates in p53 dependent apoptotic pathway[J] . Oncogene，2002，21(17)：2613-2622.
[16] WASIELEWSKI M ，ELSTRODT F，KLIJN J G，et al. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines[J] . Breast Cancer Res Treat，2006，99(1) ：20-22.
